AIM ImmunoTech Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; balance-sheet comparisons are against December 31, 2023. AIM is a clinical-stage immunopharmaceutical company focused primarily on developing Ampligen (rintatolimod). Ampligen is not FDA-approved or marketed in the United States; it is approved for severe chronic fatigue syndrome in Argentina, where commercial launch remains pending final regulatory testing and approval.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $40,000 | $49,000; down $9,000 |
| Research and development | $1.951 million | $2.052 million; down $101,000 |
| General and administrative | $3.815 million | $2.292 million; up $1.523 million |
| Operating loss | $5.734 million | $4.295 million |
| Net loss | $5.817 million | $3.661 million; loss increased 59% |
| Basic and diluted loss per share | $0.12 | $0.08 |
| Net cash used in operating activities | $4.815 million | $3.680 million |
Revenue came from the Ampligen cost-recovery and open-label access programs; the company reported no commercially saleable Alferon N Injection product. Revenue was immaterial relative to expenses, so the filing does not provide a meaningful operating margin measure. The larger net loss reflected increased G&A, particularly $1.571 million in legal professional fees, a $295,000 adverse year-over-year change in investment results, lower interest and other income, and no gain from sale of tax operating losses (versus $255,000 in Q1 2023). Lower R&D expense partially offset these items.
At March 31, 2024, cash and cash equivalents were $3.295 million and marketable investments were $7.647 million, for combined cash, cash equivalents and investments of approximately $10.942 million. Total current assets were $11.306 million; current liabilities were $9.876 million. Stockholders’ equity was $4.826 million, down from $10.234 million at year-end 2023. The filing does not present a current ratio or other specific liquidity ratio.
The company reported $2.829 million of financing cash inflows, including $2.5 million of net proceeds from a new note and $329,000 from stock issuance. Cash declined by $2.144 million during the quarter. The note has a 10% stated rate and requires payment of $3.301 million by February 16, 2026; its face amount is $3.330 million, with $2.573 million reported net of unamortized discount and fees. Approximately $1.623 million of the net carrying amount is classified as current. The lender may redeem up to $250,000 per month beginning August 2024, and specified triggering events can make the note immediately due.
Material changes and financing
- G&A increased 66% year over year, primarily because of legal fees. R&D declined about 5%.
- Cash used in operations increased by $1.135 million year over year. The company attributed part of the period’s cash-flow movements to receipt of $1.184 million related to a prior New Jersey net operating loss sale.
- Common shares outstanding rose to 50,251,933 at quarter-end from 49,102,484 at December 31, 2023. The company issued shares through its employee stock purchase plan and equity distribution agreement and issued 338,600 commitment shares to Atlas.
- The March 2024 Atlas agreement provides for discretionary stock sales of up to $15 million over 24 months, subject to registration, contractual limits and other conditions. No sales had occurred by March 31. The filing reports subsequent Atlas put notices for 206,800 shares and additional EDA sales after quarter-end.
- Management stated that current resources should fund anticipated operating needs and current clinical trials for approximately 24 months. It also said additional funding may be needed for new studies or if trials require changes or additional work; future financing is not assured and may dilute existing stockholders.
Business outlook, risks and unusual items
- Management prioritizes clinical programs in pancreatic cancer, ME/CFS and post-COVID conditions over antiviral experimentation. The AMP-270 Phase 2 pancreatic cancer trial is recruiting; the filing anticipates about 90 participants and describes a multiyear study.
- The Phase 2 AMP-518 post-COVID study enrolled 80 participants, completed treatment and follow-up, and had topline data reported in February 2024. This filing provides no clear numerical results for that study.
- After quarter-end, researchers reported topline ovarian cancer combination-trial results: 45% objective response rate in platinum-sensitive participants, 55% clinical benefit rate and median progression-free survival of 7.8 months. These are investigator-reported results, not company revenue or an FDA approval.
- Ampligen’s development remains subject to clinical and regulatory uncertainty. The company cautions that animal and early-stage findings may not predict human outcomes and that trials may fail, be delayed, require additional funding or not receive regulatory approval. Ampligen is not FDA-approved in the United States; the company’s prior ME/CFS NDA received an FDA Complete Response Letter.
- Argentina’s final release process for Ampligen remains ongoing. The filing also notes hyperinflation and a 50% currency devaluation in Argentina and says the company and its partner must assess the effect on their relationship.
- Alferon N Injection production is on hold, with no definitive timetable to resume. The company says new product batches and FDA release approval would be required before U.S. commercial sales resume.
- In a Florida case, a court issued sanctions-related rulings against AIM and its counsel and ordered further briefing on fees and a possible additional sanction. AIM estimated potential liability at approximately $200,000 but said it could not assure that estimate and was considering an appeal. A Delaware Supreme Court matter remained under consideration after April 10, 2024 oral argument.
- Deferred 2023 bonuses totaling $500,000 were paid in May 2024. In April 2024, 689 Series B preferred shares expired without conversion.
Key facts for investors to verify
- Whether cash burn and available liquidity support management’s stated approximately 24-month funding horizon, considering the note’s repayment terms and continuing trial commitments.
- Atlas and EDA share issuance, registration effectiveness, actual proceeds, pricing and dilution; confirm subsequent transactions against later filings.
- Full clinical data and safety findings for AMP-518 and the ovarian cancer study, including study design, participant numbers, follow-up and whether findings are peer-reviewed.
- Recruitment, costs, timeline and funding for AMP-270 and other priority studies, as well as any FDA or EMA feedback.
- Progress toward final Argentine approval and commercial launch of Ampligen, and the effect of currency conditions and the GP Pharm relationship.
- Developments in the Florida sanctions matter and Delaware litigation, including any final fee or sanction amounts.